2026 Life Sciences Regulatory Updates for Asia

As Asia’s life sciences regulatory landscape evolves in 2026, companies face significant changes that demand strategic preparation. India is piloting electronic Common Technical Document (eCTD) submissions, signaling a shift to digital regulatory processes. China is introducing a revised Good Manufacturing Practice (GMP) framework for medical devices, emphasizing lifecycle risk management and quality assurance. Ahead of the pack, Japan is transitioning to eCTD version 4.0, requiring enhanced metadata handling and structured submissions. Meanwhile, South Korea is accelerating drug approvals through expedited review pathways and fast-track programs, creating opportunities for quicker market entry. These developments reflect a regional trend toward harmonization, digitalization, and efficiency in regulatory systems. 

India: eCTD Pilot in the SUGAM Portal 

India’s Central Drugs Standard Control Organization (CDSCO) initiated an eCTD pilot in the SUGAM Portal in 2025. While not explicitly stated to take effect in 2026, this signals an effort by CDSCO to align its electronic submission requirements with eCTD 4.0. 

Developed by the ICH, eCTD 4.0 aims to improve submission management with lifecycle management and tracking, along with single submission units. While no national regulatory agency has adopted it (Japan’s PMDA is aiming to launch their eCTD 4.0 system in 2026), many agencies, including the FDA and EC, have started the rollout of pilot projects. 

To begin preparing for the eCTD update, companies operating in India should digitize their regulatory workflows and ensure compatibility with eCTD requirements. If possible, participate in the SUGAM Portal pilot and participate in discussions with CDSCO. Use information from other jurisdictions to see what the implementation could look like, when it happens. 

China: Revised GMP for Medical Devices 

China’s National Medical Products Administration (NMPA) released the revised version of the Good Manufacturing Practice for Medical Devices on November 4th, to come into effect November 1st, 2026. 

The update adds 3 new chapters on quality assurance, validation and verification, and contract manufacturing and outsourcing. The updates reinforce systemic quality risk management throughout the product life cycle, strengthen quality assurance requirements in a QMS, and clarifies management requirements in contract manufacturing, criteria for validation and verification and effective control of key elements, and applications for AI.  

This GMP update is reflective of many regulatory updates across the globe, implementing additional requirements for risk systems and AI. For companies operating in China, look to upgrade and update their QMS to meet the new GMP system, and perform a gap analysis to see if they can meet the new requirements. When investing in digital systems, ensure that they have bult in documentation and traceability capabilities. For more information, refer to the official notice here.

Japan: eCTD Implementation 2026 

Japan’s PMDA is at the forefront of eCTD 4.0 implementation. The PMDA was the first regulator to pilot an implementation of eCTD 4.0, back in 2021. Based on their results, the PMDA is expected to have mandatory implementation of eCTD 4.0 in 2026. 

For companies operating in Japan, there is still some time to prepare their quality system for this update, however that time is short. PMDA is currently accepting voluntary eCTD 4.0 submissions, so early adopters can gain valuable experience. Firms should ensure that their regulatory publishing tools support eCTD 4.0, including additions like structured content, metadata, and lifecycle management. Developing a migration plan, starting with a gap analysis of current eCTD processes vs 4.0 processes, will be instrumental in driving this change. The PMDA eCTD 4.0 implementation guide can be found here.

South Korea: Expedited Drug Review & Fast‑Track Programs 

In late 2025, the Minister of Food and Drug Safety announced additional investment into the Ministry of Food and Drug Safety (MFDS) in 2026, with focus on hiring additional approval and review personnel and introducing AI based reviews. 

The MFDS has already been working to decrease product review time by deploying product specific review teams and parallel inspections. This increase in support will have significant benefits not only for these drug review programs but also for fast-track streams such as the Global Innovative products on Fast Track program (GIFT). GIFT facilitates the expedited review of innovative medicinal products for market approval in South Korea, which can be shorted to up to 75% of the standard review time. Additionally, GIFT has more plans to adopt internationally harmonized regulations, non-safety related post-approval submissions, and providing public access to a list of GIFT designated products. 

There is opportunity for faster market entry for innovative products in South Korea, provided that interested parties have robust early data and have been engaging with the MFDS. For firms looking to take advantage of this boost to regulatory reviews, start by identifying products eligible for fast-track and prepare strong early clinical and quality data in order to build a relationship with the MFDS. More information can be found on the official MFDS website.  

Taiwan: Mandatory Cosmetic Product Information Files 

The Taiwan Food and Drug Administration (TFDA) began enforcing the Product Information File system through a phased process featuring an expanding product list in each phase starting in 2024. As of July 1st 2026, all cosmetic products will be required to have PIFs before being marketed, sold, or provided for consumer use in Taiwan. 

The PIFs must include information such as product details, ingredient names and concentrations, manufacturing process, toxicological data, stability test reports, and a comprehensive safety assessment, with signoffs by a qualified safety assessor. The (TFDA aims to use documentation and scientific evaluations to enhance the safety of marketed cosmetic products. 

For companies looking to expand to the Taiwanese cosmetics market, the TFDA provides online training through their Medical Device and Cosmetic e-Learning Platform, along with guidelines and document templates for various product types. More information about this program can be found on the official TFDA website.

Conclusion 

For companies operating in Asian markets, proactive adaptation is essential. Investing in digital infrastructure, upgrading quality systems, and training regulatory teams will be critical to meet new regulatory requirements. Early engagement with local authorities, conducting gap analyses, and leveraging fast-track opportunities can help organizations maintain competitiveness and avoid costly delays. By embracing these changes now, life sciences firms can position themselves for success in an increasingly innovation-driven regulatory environment across Asia. To learn more about global regulatory updates, and to see how a state-of-the-art eQMS system can help navigate these changes, learn more about ACE.